Gastric Cancer Drugs Market Report 2026

The gastric cancer drugs market size has grown strongly in recent years. It will grow from $4.9 billion in 2025 to $5.39 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to rising prevalence of gastric cancer, limited awareness of early detection, reliance on conventional chemotherapy, increasing adoption of hospital-based treatment, high cost of branded drugs.

The gastric cancer drugs market size is expected to see rapid growth in the next few years. It will grow to $8.14 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to advancements in targeted therapies, growth in immunotherapy adoption, expansion of precision medicine, development of oral and injectable formulations, increasing government and private funding for cancer research. Major trends in the forecast period include personalized gastric cancer therapies, development of targeted drug delivery systems, increased use of combination therapies, expansion of outpatient cancer treatment services, growth in supportive care and symptom management.

The growing global aging population is expected to drive the expansion of the gastric cancer drug market in the coming years. An aging population refers to a demographic condition where a significant portion of a country’s or region’s residents are older, typically 65 years and above. This situation arises from a sustained increase in life expectancy combined with declining birth rates, resulting in a higher proportion of elderly individuals relative to the total population. Older patients often have limited tolerance for certain cancer treatments, including surgery or chemotherapy. Consequently, there is a rising need for more tailored treatment options, including drugs, to address the specific requirements and tolerances of elderly patients. For example, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government institution, there were 12.7 million people aged 65 or older in the UK in 2022, accounting for 19% of the total population. This figure is projected to increase to 22.1 million by 2072, representing 27% of the population. Therefore, the gastric cancer drug market is expected to witness growth in the future, fueled by the expanding elderly population.

Numerous companies in the gastric cancer drug market are concentrating on developing innovative therapies, such as CLDN18.2-targeted treatments, to enhance therapy effectiveness and offer more personalized options for patients. CLDN18.2-targeted treatment refers to therapies aimed at claudin 18.2 (CLDN18.2), a protein predominantly expressed in certain epithelial tissues, including the gastric epithelium. For instance, in October 2024, Astellas Pharma Inc., a Japan-based company, received approval from the Food and Drug Administration (FDA), a US federal agency responsible for public health, for VYLOY (zolbetuximab). VYLOY (zolbetuximab) is the first and only CLDN18.2-targeted treatment for advanced gastric and gastroesophageal junction cancer with CLDN18.2-positive tumors. The therapy is administered alongside fluoropyrimidine- and platinum-based chemotherapy regimens and is indicated for adults with locally advanced unresectable gastric or gastroesophageal junction adenocarcinoma.

In January 2023, Leap Therapeutics Inc., a US-based biotechnology company, acquired Flame Biosciences, Inc. for an undisclosed sum. Through this acquisition, Leap Therapeutics Inc. aims to strengthen its oncology pipeline and broaden its therapeutic offerings. The acquisition also enables Leap to integrate Flame's clinical-stage anti-Claudin18.2 antibody, FL-301, under development for gastric and pancreatic cancers, into its portfolio. Flame Biosciences Inc. is a US-based biotechnology company specializing in gastric cancer therapies.

Major companies operating in the gastric cancer drugs market are F. Hoffmann-La Roche, Eli Lilly and Company, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Novartis Oncology, Arlak Biotech (India), CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene (China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc. (Japan), Daiichi Sankyo, AstraZeneca plc, GlaxoSmithKline plc, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Merck & Co. Inc., Pfizer Inc., Sandoz AG (Novartis), Eurofarma Laboratórios S.A., TUTEUR Argentina / Pierre Fabre Group, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Mylan Laboratories, Gilead Sciences, BMS.

North America was the largest region in the gastric cancer drugs market in 2025. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastric cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the gastric cancer drugs market by increasing import costs for active pharmaceutical ingredients (APIs) and specialized formulations, particularly affecting injectable and targeted therapy segments. Regions such as North America and Europe, which import key components from Asia, face higher production costs and supply chain delays. While this may temporarily slow the adoption of certain therapies, it has encouraged local manufacturing initiatives and cost-optimization strategies, potentially leading to more competitive pricing and innovation in drug delivery systems.

The gastric cancer drugs market research report is one of a series of new reports that provides gastric cancer drugs market statistics, including gastric cancer drugs industry global market size, regional shares, competitors with a gastric cancer drugs market share, detailed gastric cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastric cancer drugs industry. This gastric cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gastric cancer drugs are anti-cancer medications that can be taken orally as tablets or administered through a vein (via IV line or central venous catheter). This therapy is effective for cancers that have metastasized beyond their original site, as these medications circulate through the bloodstream and reach all parts of the body.

The primary types of gastric cancer drugs include doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, and trastuzumab. Sunitinib acts as a chemotherapeutic agent and receptor tyrosine kinase inhibitor, treating renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GIST) that are resistant to imatinib. These drugs are delivered both orally and parenterally and are utilized by hospitals, clinics, and other healthcare facilities.

The gastric cancer drugs market consists of sales of cyramza, docetaxel, and doxorubicin hydrochloride. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.